Publication Name	World Journal of Cardiology
Manuscript ID	14319
Country	Italy

Received	2014-09-28 17:38
Peer-Review Started	2014-09-28 19:14
To Make the First Decision	2014-12-17 11:24
Return for Revision	2014-12-19 12:09
Revised	2014-12-28 03:40
Second Decision	2015-01-21 20:52
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2015-02-02 20:13
Articles in Press	2015-02-02 20:13
Publication Fee Transferred
Edit the Manuscript by Language Editor	2015-03-14 18:22
Typeset the Manuscript	2015-05-04 13:49
Publish the Manuscript Online	2015-05-21 13:54

ISSN	1949-8462 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Cardiac & Cardiovascular Systems
Manuscript Type	Field of Vision
Article Title	Insights into cardio-oncology: Polypharmacology of quinazoline-based 1-adrenoceptor antagonists
Manuscript Source	Invited Manuscript
All Author List	Salvatore Patanè
Funding Agency and Grant Number
Corresponding Author	Salvatore Patanè, MD, Cardiologia Ospedale San Vincenzo, Taormina (Me) Azienda Sanitaria Provinciale di Messina, Contrada Sirina, 98039 Taormina, Messina, Italy. patane-@libero.it
Key Words	Cardio-oncology; Multidrug resistance; Prazosin; Terazosin; Doxazosin
Core Tip	New uses of cardiovascular drugs with proven experience and without high cost have been emerging, including to have anticancer abilities by targeting human ether-a-go-go-related gene K(+) channels, epidermal growth factor receptors, vascular endothelial growth factor receptors, as well as to overcome cancer multidrug resistance. Quinazoline-based ?1-adrenoceptor antagonists (doxazosin, prazosin, and terazosin) exhibit anticancer abilities and emerging findings indicate that these drugs may have a significant role in uncontrolled hypertensive cancer patients without signs of ischemia.
Publish Date	2015-05-21 13:54
Citation	Patanè S. Insights into cardio-oncology: Polypharmacology of quinazoline-based 1-adrenoceptor antagonists. World J Cardiol 2015; 7(5): 238-242
URL	http://www.wjgnet.com/1949-8462/full/v7/i5/238.htm
DOI	http://dx.doi.org/10.4330/wjc.v7.i5.238

Full Article (PDF)	WJC-7-238.pdf
Full Article (Word)	WJC-7-238.doc
Manuscript File	14319-Review.doc
Answering Reviewers	14319-Answering reviewers.pdf
Conflict-of-Interest Disclosure Form	14319-Conflict-of-interest statement.pdf
Copyright License Agreement	14319-Copyright assignment.pdf
Peer-review Report	14319-Peer-review(s).pdf
Scientific Misconduct Check	14319-CrossCheck.jpg
Scientific Editor Work List	14319-Scientific editor work list.pdf